Brief: GlycoMimetics Announces Strategic Review, Restructuring Plan
25/07/2024 14:02
July 25 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS ANNOUNCES STRATEGIC REVIEW AND CORPORATE
RESTRUCTURING PLAN
* GLYCOMIMETICS INC: WILL REDUCE ITS WORKFORCE BY
APPROXIMATELY
80%
* GLYCOMIMETICS INC - CASH EXPECTED TO FUND COMPANY INTO Q2
2025
* GLYCOMIMETICS INC: CASH AND CASH EQUIVALENTS ARE EXPECTED
TO
FUND COMPANY INTO Q2 OF 2025
* GLYCOMIMETICS INC - FDA REQUIRES ADDITIONAL TRIAL FOR
UPROLESELAN IN AML
Source text for Eikon: ID:nBw2T2MC6a
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering